Growth hormone and respiratory compromise in Prader-Willi Syndrome

S S I Wilson; A M Cotterill; M-A Harris

doi:10.1136/adc.2005.086090

Growth hormone and respiratory compromise in Prader-Willi Syndrome

Arch Dis Child. 2006 Apr;91(4):349-50. doi: 10.1136/adc.2005.086090.

Authors

S S I Wilson¹, A M Cotterill, M-A Harris

Affiliation

¹ Department of Respiratory and Sleep Medicine, Mater Children's Hospital, South Brisbane, Australia.

Abstract

Recombinant human growth hormone (rhGH) therapy in Prader-Willi syndrome (PWS) causes increased basal metabolic rate and oxygen consumption, and hence increased ventilatory load. The case of an adolescent with PWS who experienced respiratory deterioration with an increase in rhGH and improvement with cessation of therapy is reported.

Publication types

Case Reports

MeSH terms

Adolescent
Human Growth Hormone / adverse effects*
Human Growth Hormone / therapeutic use
Humans
Male
Polysomnography
Prader-Willi Syndrome / drug therapy*
Recombinant Proteins / adverse effects
Recombinant Proteins / therapeutic use
Respiratory Insufficiency / chemically induced*

Substances

Recombinant Proteins
Human Growth Hormone